$FATE

Valamehr Bahram (President and CEO) sold 43,947 shares of FATE THERAPEUTICS INC (FATE) at $2.46 ($0.11M total) on 2026-08-04.

Fate Therapeutics (NASDAQ: FATE) said it granted inducement awards on Aug. 1, 2026 under Nasdaq Rule 5635(c)(4). One new non-executive employee received non-qualified stock options for 37,300 shares at $2.45 per share. Two employees received RSUs for 45,300 shares. Options and RSUs vest over four years.

Fate Therapeutics (NASDAQ: FATE) said the FDA cleared its IND for FT839, an off-the-shelf dual CAR T-cell candidate targeting CD19 and CD38. The company plans a Phase 1/2 multi-indication basket trial starting in 2H 2026 to test FT839 with standard-of-care for autoimmune diseases, with or without conditioning chemotherapy. Key initial indications include rheumatoid arthritis and lupus.

Fate Therapeutics (NASDAQ: FATE) said it will present preliminary Phase 1 basket-trial data for its off-the-shelf CD19 CAR T-cell FT819 in systemic sclerosis at the ISSCR 2026 meeting (July 8–11). As of June 12, four patients showed rCRISS25+ and mean mRSS improvement at 3 months, with no CRS, ICANS, GvHD, hypogammaglobulinemia, or deaths reported.

FATE THERAPEUTICS INC (FATE) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 fate-ex10_1.htm EX-10.1 EX-10.1 FATE THERAPEUTICS, INC. THIRD AMENDED AND RESTATED 2022 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Fate Therapeutics, Inc. Third Amended and Restated 2022 Stock Option a

The article says Fate Therapeutics’ cash burn is about $108m, roughly 33% of its $331m market capitalization. It notes the company’s cash runway appears “reassuring,” but flags falling revenue as a concern. The piece frames cash burn as a risk and mentions multiple warning signs, without providing further figures.

Fate Therapeutics showcased positive clinical data for its off-the-shelf CAR T-cell programs FT819, FT839, and FT836 at the 2026 ASGCT Annual Meeting. FT819 demonstrated efficacy in systemic lupus erythematosus (SLE) patients without conditioning chemotherapy, achieving lupus low disease activity and B cell remodeling. Preclinical data for FT839 and FT836 also showed promising results for autoimmune diseases and cancer, respectively, highlighting the potential for less intensive or no conditioning chemotherapy in cellular immunotherapies.

Fate Therapeutics officer Cindy Tahl exercised stock options to acquire 166,664 shares of FATE common stock on May 6, 2026. This transaction involved exercising options at $1.05 and $1.32 per share, and she now directly holds 609,301 shares. The exercises were compensation-related and no open-market sales were reported.

Fate Therapeutics, Inc. announced its management will participate in five investor conferences during the second quarter of 2026, including virtual and in-person events like the Needham, Bank of America, H.C. Wainwright, Jeffries, and Goldman Sachs healthcare conferences. The company, a clinical-stage biopharmaceutical firm, focuses on developing iPSC-derived cellular immunotherapies for cancer and autoimmune diseases. Webcasts of presentations, if available, will be on their website.

Fate Therapeutics (NASDAQ: FATE) announced its management will participate in five investor conferences during Q2 2026, including the Needham Virtual Healthcare Conference, Bank of America Healthcare Conference, H.C. Wainwright BioConnect, Jefferies Global Healthcare, and Goldman Sachs Global Healthcare. Presentations or fireside chats may occur at these events, with live webcasts and archived replays available on the company's website. This follows a pattern of positive market reactions to conference and earnings announcements, contrasting with modest negative responses to routine equity awards.